Background: In April 2011 a group of Latin American (LA) allergy experts, leaders in their countries in the area of immunotherapy, met in Cordoba, Argentina, to discuss how allergy and allergen-specific immunotherapy (ASIT) can be improved in the region. The need for a situational sketch was expressed. Methods: A questionnaire on allergy training (AT), ASIT, extracts and legislation was sent out to 22 leaders in the field of nine LA countries to obtain an overview of the LA situation. Results: Results are presented with descriptive statistics. All 22 questionnaires were returned (9 countries). AT in 56% of the surveyed LA countries is at the third-level of medical care, after a core-training of 2 to 3 years internal medicine or pediatrics; in 3 countries it is a second-level career and in one country there is no AT. Board certification with exam is only mandatory in a third of the countries; recertification being obtained without exam. Mostly, training is in general allergy; pediatric AT only exists in 2 countries. Both sublingual (SLIT, only in the form of drops) and subcutaneous (SCIT) immunotherapy are practiced in all countries, from the age of 3 years (mean, range 1-5 years) onward. As no strict legislation exists IT can be managed by non-allergists in 7/9 countries. Mixed extracts are used with mostly 3 to 5 allergens/vial (range 2 to 6-10 allergens/vial) and all countries have bacterial vaccine. SCIT extracts come from US and European (89%) and 56% local providers. SLIT extracts are almost exclusively from Europe (Spain), but in Argentine, Brazil, and Mexico also local SLIT extracts exist. There is rudimentary regulation concerning extract potency in 2 countries. IT is generally paid for by private patients. Insurance companies reimburse IT in 56% of the countries, the social security system in 33% and in one country selected third level governmental hospitals supply IT. Publications on adverse events with IT are starting to appear (3 countries) and 3 countries have their own guidelines on IT (one only in pediatrics). Conclusions: A clearer picture where and how to improve AT and ASIT in LA has been obtained; however, unmet needs on ASIT are still pending.
Clinical Effects of Immunotherapy in Patients with Allergic Disease in the National Institute of Respiratory Diseases
Ma del Rosario Gonzalez Galarza, MD, Ma de la Luz Garcia Cruz, MD, Fernando Ramirez Jimenez, MD, Karla Paola Ruiz Cervantes, MD, Carlos Guillermo Najera Villatoro, MD, and Luis Manuel Teran Juarez, PhD. Clinical Immunology and Allergy, National Institute of Respiratory Disease, Distrito Federal, Mexico. Background: Previous studies have shown that after the treatment with immunotherapy there is a reduction in the number of visits to emergency services for asthma crisis, a significant improvement in pulmonary function tests: forced vital capacity (FVC), forced expiratory volume percentage in 1 second (FEV1%) and in the percentage of peak expiratory flow (PEF%) and the dose and number of drugs. There is also evidence of decreased response to skin tests and IgE levels with immunotherapy specific to Dermatophagoides pteronyssinus (Dpt). Methods: The objective of this study was to evaluate the clinical effects of immunotherapy in patients with allergic disease treated at the National Institute of Respiratory Diseases in Mexico City, Mexico. There was a random selection in a prospective study of 99 patients with positive skin tests and more than 18 months of treatment with subcutaneous immunotherapy specific to epithelia, pollens from trees, grasses and weeds; at the beginning and the end of the immunotherapy there was an evaluation of the scale of rhinitis symptoms and asthma control; pulmonary function tests were performed as well (spirometry). Results: At the initial evaluation, 97% of patients presented moderate to severe persistent rhinitis, 80% of patients with asthma was uncontrolled; after 18 months with specific immunotherapy 80% of patients presented moderate intermittent rhinitis and asthma control was achieved in 85% of the patients. The FEV1 average increased from 78% at the beginning to 89% (P , 0.001). The average bump at the beginning of the specific immunotherapy was 12 cm for Dpt, for trees 10 cm, for weeds 8 cm and for grasses 8 cm; at the end of the SIT the average bump for Dpt was 10 cm, trees 2 cm, weeds 1cm and grass 0 cm (P value , 0.01). Conclusions: The specific subcutaneous immunotherapy had beneficial clinical effects in patients with allergic disease, with significant improvement in pulmonary function tests and reduced positivity in skin tests, specifically for patients who were sensitive to pollens from trees, weeds and grasses.
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Approach of Paediatric Allergists to Allergen Immunotherapy in Severe Persistent Allergic Rhinitis Alessandro Fiocchi, MD, 1 Giovanni Passalacqua, MD, 2 Sergio Bonini, MD, 3 Franco Frati, MD, 4 Luigi Terracciano, MD, 1 Sandra Senecic, BSc, 5 and Oscar Mazzina, RD 1 . 1 Melloni Paediatria, Milano, Italy; 2 Allergy & Respiratory Diseases, Universita Degli Studi Di Genova, Genoa, Italy; 3 Second University of Naples, Rome, Italy; 4 Department of Medical and Surgical Specialties and Public Health, Perugia, Perugia, Italy; 5 Allegria, Milan, Italy. Background: Hospital-based allergists manage children with allergic rhinitis (AR) in Lombardy (paediatric population 900,000 ca). These specialists' perception of severity in referrals was assessed by questionnaire. Methods: During May 2011, a spreadsheet was e-mailed to 51 paediatric allergy units, followed up by telephone interviews by trained volunteers providing online assistance for compilation. Data were collected in preschoolers (group I), school-age (group II) and adolescents (group III). Results: Overall response was 66.6%. AR estimates among these referrals were 75.6% (70.6% in group I, 75.5% in group II and 82.9% in group III). AR alone occurred in 18. 7% (21.4%, 17.2%, and 19 .1%) of cases. Co-morbidities included asthma in 18.1% (30.1%, 14.1%, and 13.4%), conjunctivitis in 25.5% (13.8%, 27.8%, and 34.6%), or both in 13. 4% (5.3%, 16.4%, and 15.7% 
